Many mutations in receptor kinases that lead to cancer allow the dimerization and activation of the receptor, even in the absence of signaling molecule. an example of this is a mutant form of the egf receptor kinase called her2/neu. an antibody that prevents dimerization of her2/neu receptor kinases is being tested for its effectiveness in stopping cancer. at which stage would this drug work?

a.
it would prevent the signaling cell from producing the signal.

b.
it would prevent the receptor from binding to the signal.

c.
it would prevent the receptor from becoming activated.

d.
it would prevent the termination of the signal.